Hello, I'm Stephen Carroll. I'm in Brussels, where many of Europe's biggest decisions get made. And I'm Caroline Hepker in London. We're the hosts of the Bloomberg Daybreak Europe podcast. We're up early every weekday, keeping an eye on what's happening across Europe and around the world. We do it early so the news is fresh, not recycled, and so you know what actually matters as the day gets going. From Brussels, I'm following the politics, policy and the people shaping the European Union right now. And from London, I'm looking at what all that means for markets, money and the wider economy. We've got reporters across Europe and around the globe feeding in as stories break. So whether it's geopolitics, energy, tech or markets, you're hearing it while it happens. It's smart, calm and to the point. And it fits into your morning. You can find new episodes of the Bloomberg Daybreak Europe podcast by 7am in Dublin or 8am in Brussels, Berlin and Paris. on Apple, Spotify, YouTube, or wherever you get your podcasts. Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report. Your roundup of companies making moves in the stock market, harnessing the power of Bloomberg data. Let's take a look at some stocks on the move today in Europe. I'm Tom McKenzie with Caroline Hepkite. We're joined now by Bloomberg's breaking news editor, Louise Moon. And Louise, we've got the broader market sentiments factor in, but also the earnings story, Anovo Nordisk, the maker, of course, of obesity drugs, benefiting from a dose of optimism. Indeed, yes. They had their first quarter results and sales essentially being fuelled by their new WeGoV obesity pill And as a result they saying that declines this year won be as bad as expected So they saying that the worst drop for the full year profit in sales will be about 12 They had said about 13%, so slightly less than they had expected. And this is all part of their race to essentially catch up with their rival Eli Lilly in America. So, they obviously lost market share originally to Eli Lilly's shot version and they kind of failed to be there, failed to capitalize on being first to market with that product. And so, the question is now, can they really compete with this pill version and compete competitively with Eli Lilly? So, so far, it's looking good. An analyst is saying that it's encouraging, there's good momentum with sales of this pill and it should help to drive the stock. and we're seeing that this morning, shares surged in Copenhagen as much as just over 9%. So positive news on that front. But yeah, it will remain to be seen how competitive they will be with this drug with Eli Lilly. Yeah, it'll be interesting to see that. Yeah, not just the injectables, but also pill forms of this obesity drug. Next, also seemed to have surprised the market, the retailer in the UK. How did they manage that? They have, yeah. So their first quarter came in a lot stronger than expected. sales-wise, and they slightly, very slightly raised their guidance for the full year. They are known for doing that anyway, so that's somewhat expected, but they did slightly raise their guidance. And that is kind of easing concern over the Middle East and the whole environment. And that's really what's being focused on, that bit of positivity from Nexus Morning pushing shares higher There are still kind of shadows on the horizon You could say the Iran war is pushing up costs it pushing up inflation it denting companies savings and consumer confidence And Nex really noted that this morning. They're expecting full-year cost increases directly as a result of the war to reach £47 million. They had before said £15 million in March, which initially covered the first three months of the war. Now they're expecting a £47 million hit. hit. As a result of that, they're planning price increases internationally, so not yet in the UK, and cost savings, unspecified cost savings, but cost savings. So, Bloomberg Intelligence saying that they've lifted their guidance, but they're showing that they're prepared to raise prices to protect their own profits. But as I say, the positivity element is being focused on as shares are up. And Louise, briefly, Lufthansa and jet fuel shortages came through with a loss, but less bad maybe than some had expected. Yeah, so they've warned of these mounting risks, surge in fuel costs, possible supply crunch there as well. But they say that they're going to mitigate this with a bunch of things. So high revenue from tickets, further efficiency, again, unspecified. But shares rose because they did reiterate guidance despite all of that. The Stock Movers Report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street. And for the latest market-moving headlines, listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com, and on Apple CarPlay and Android Auto with the Bloomberg Business App. This is Tom Keen inviting you to join us for the Bloomberg Surveillance Podcast It about making you smarter every business day I Paul Sweeney We bring you complete coverage of the U market open We cover stocks bonds commodities even crypto all the information you need to excel And I'm Alexis Christophorus. Bloomberg Surveillance also brings you the analysis behind the headlines. We do that through conversations with the smartest names in economics, finance, investment, and international relations. We do all this live each and every weekday that bring you the best analysis in our daily podcast. Search for Bloomberg Surveillance on Apple, Spotify, YouTube, or anywhere else you listen. On the East Coast, listen at lunch. And on the West Coast, listen as soon as you wake up. That's the Bloomberg Surveillance Podcast with Tom Keen, Paul Sweeney, and me, Alexis Christophorus. Subscribe today wherever you get your podcasts. Bloomberg Surveillance, essential listening each and every business day. tech sector to new frontiers and the politics that shape global tech markets. We do this all every weekday, then bring you the most important conversations and analysis in our podcast. Search for Bloomberg Tech on YouTube, Apple, Spotify, or anywhere else you listen. Join us every afternoon on your commute home and stay ahead of the tech news cycle. That's the Bloomberg Tech Podcast. I'm Caroline Hyde in New York. And I'm Ed Ludlow in San Francisco. Subscribe today, wherever you get your podcasts.
